The Non-Surgical segment held a 67.49% share of the crohn's disease therapeutics market in 2025, reflecting its central role in long-term disease control and routine patient management. This segment leads because treatment pathways in Crohn’s disease typically begin with pharmacological intervention to reduce inflammation, manage flares, and maintain remission before invasive options are considered. Its broad use across different stages of care, along with the need for ongoing therapy in many patients, continues to sustain the segment’s leadership in the crohn's disease therapeutics market.

Surgical is the fastest-growing segment in the crohn's disease therapeutics market as a result of the practical need to address complications that are not adequately managed through medication alone. Growth is being reinforced through cases involving strictures, fistulas, abscesses, and recurrent disease activity where operative intervention becomes necessary despite advances in non-surgical treatment. Compared with non-surgical care, surgery gains momentum when disease progression creates a clear clinical requirement for structural correction or complication management, making this segment increasingly relevant in more complex treatment settings.

Route of Administration Segment Analysis: Injectable (Largest Segment) vs Oral (Fastest-Growing Segment)

Within the crohn's disease therapeutics market, Injectable accounted for the largest share in 2025, reinforced through its established use in delivering advanced therapies for moderate to severe disease. The segment maintains leadership because injectable administration is commonly associated with treatment approaches used when sustained disease control is required and when patients need therapies that may not be effectively delivered through simpler routes. Its entrenched role in specialist-led care and use in patients requiring intensive therapeutic management help preserve its leading share in the crohn's disease therapeutics market.

Oral is the fastest-growing route of administration in the crohn's disease therapeutics market, encouraged by increasing preference for treatments that fit more easily into long-term daily management. Its momentum relative to injectable options comes from the practical advantages of convenience, easier administration, and reduced dependence on clinical settings for treatment delivery. As patient and provider attention shifts toward less burdensome therapy experiences where clinically appropriate, oral treatments are seeing wider adoption across the crohn's disease therapeutics market.